Profund Advisors’s Krystal Biotech KRYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.43M Buy
7,313
+1,543
+27% +$534K 0.07% 164
2026
Q2
$2.14M Sell
5,770
-3,020
-34% -$902K 0.06% 181
2026
Q1
$2.27M Sell
8,790
-1,097
-11% -$292K 0.08% 174
2025
Q4
$2.44M Buy
9,887
+1,557
+19% +$328K 0.07% 173
2025
Q3
$1.47M Buy
8,330
+164
+2% +$24.5K 0.05% 248
2025
Q2
$1.12M Buy
8,166
+2,203
+37% +$324K 0.04% 277
2025
Q1
$1.08M Sell
5,963
-358
-6% -$60.2K 0.05% 280
2024
Q4
$990K Sell
6,321
-3,664
-37% -$650K 0.04% 301
2024
Q3
$1.82M Buy
9,985
+1,292
+15% +$249K 0.07% 207
2024
Q2
$1.6M Buy
8,693
+140
+2% +$23.5K 0.06% 215
2024
Q1
$1.52M Sell
8,553
-5,229
-38% -$726K 0.06% 224
2023
Q4
$1.71M Buy
13,782
+1,542
+13% +$171K 0.07% 203
2023
Q3
$1.42M Buy
12,240
+2,375
+24% +$290K 0.08% 202
2023
Q2
$1.16M Sell
9,865
-1,716
-15% -$175K 0.06% 283
2023
Q1
$927K Buy
+11,581
New +$910K 0.06% 320

Other funds holding KRYS

Profund Advisors's KRYS Position: Q3 2026 in Review

Profund Advisors increased its Krystal Biotech (KRYS) stake by 27% in Q3 2026, buying an estimated $534K and bringing the position to 7,313 shares worth $2.43M. The position accounts for 0.07% of the portfolio, ranked #164.

Profund Advisors first reported a position in KRYS in Q1 2023 and has held it in 15 quarters since. The position peaked at $2.44M in Q4 2025. 442 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Profund Advisors held 7,313 shares of Krystal Biotech worth $2.43M as of Q3 2026.
  • Profund Advisors bought 1,543 Krystal Biotech shares in Q3 2026, an estimated $534K.
  • Krystal Biotech made up 0.07% of Profund Advisors's portfolio in Q3 2026, its #164 holding.
  • Profund Advisors first reported a position in Krystal Biotech in Q1 2023 and has held it in 15 quarters since.
  • Profund Advisors's Krystal Biotech position peaked at $2.44M in Q4 2025.
  • 442 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.